Carisma Therapeutics, Inc. (CARM) Financial Analysis & Valuation | Quarter Chart

Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeri... more
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) m... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$188,303ExchangeOTC
SectorHealthcareIndustryBiotechnology
CountryUSCEOCraig R. Jalbert
IPO Date2014-02-06CAGR
Employees46Websitecarismatx.com
Div. YieldPayout Ratio
Buy Back YieldTotal Yield
CARM chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
EV$9.62MP/E0.01Forward P/EPEG
P/SP/BP/CFP/FCF
Sales$52.63MSales 1Y159.68%Sales 3Y101.63%Sales 5Y368.42%
EPS$0.31EPS 1YEPS 3YEPS 5Y
Sales QoQEPS QoQ-565.22%Sales QoQ AvgEPS QoQ Avg-143.2%
Gross Margin98.05%Operating Margin20.61%Profit Margin15.28%ROCE-4204.26%
ROA123%ROE-29%Altman Z Score-45.89Piotroski Score3
Current Ratio0.86Quick Ratio0.86Cash Ratio0.41Op. CF Ratio0.28
Debt/Equity-0.88Debt/Assets0.12Lt Debt/Equity-0.7Lt Debt/Cap.
Intrst Cov.Inventory TurnoverAsset Turnover8.03Receivables Turnover32.17
Enterprise Value$9.62MP/E Ratio0.01
Forward P/EPEG Ratio
P/S RatioP/B Ratio
P/CF RatioP/FCF Ratio
EPS$0.31EPS Growth 1Y
EPS Growth 3YEPS Growth 5Y
Revenue Growth 1Y159.68%Gross Margin0.98%
Operating Margin0.21%Profit Margin0.15%
ROE-0.29%ROA1.23%
ROCE-42.04%Current Ratio0.86
Quick Ratio0.86Cash Ratio0.41
Debt/Equity-0.88Interest Coverage
Altman Z Score-45.89Piotroski Score3

Carisma Therapeutics, Inc. (CARM) valuation & financials

Carisma Therapeutics, Inc. (CARM) has a market capitalization of $188,303 and trades at a price-to-earnings ratio of 0.0. It operates in the Healthcare sector (Biotechnology).

Carisma Therapeutics, Inc.'s revenue grew +159.7% over the last year.

Carisma Therapeutics, Inc.'s next earnings report is scheduled for May 28, 2026 after market close; analysts estimate EPS of $-0.15.

📈 Analysts estimate CARM EPS of $-0.15 for the upcoming quarter. See Carisma Therapeutics, Inc. revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

Carisma Therapeutics, Inc. (CARM) — frequently asked questions

When does Carisma Therapeutics, Inc. (CARM) report earnings next?

Carisma Therapeutics, Inc. is expected to report earnings on May 28, 2026 after market close. Analysts estimate EPS of $-0.15.

What is Carisma Therapeutics, Inc.'s market cap?

Carisma Therapeutics, Inc. (CARM) has a market capitalization of $188,303.

What is CARM's P/E ratio?

Carisma Therapeutics, Inc. trades at a price-to-earnings ratio of 0.0, with trailing twelve-month EPS of $0.31.

How fast is Carisma Therapeutics, Inc. growing?

Carisma Therapeutics, Inc.'s revenue grew +159.7% over the last year.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)